TGFB1 and acute myeloid leukemia: Furthermore, when comparing OS in secondary AML patients based on TGF-β1 staining, those with moderate/strong staining had longer survival (31 vs 57.8 months), though the difference was not statistically significant (P ═ 0.4568) (Figure 4).